keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis C therapy

keyword
https://www.readbyqxmd.com/read/28225575/25-hydroxy-vitamin-d-suppresses-hepatitis-c-virus-replication-and-contributes-to-rapid-virological-response-of-treatment-efficacy
#1
Jee-Fu Huang, Yu-Min Ko, Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Meng-Hsuan Hsieh, Ching-I Huang, Hua-Ling Yang, Shu-Chi Wang, Zu-Yau Lin, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang
AIM: 25-hydroxy vitamin D (Vit D) plays a role in treatment outcomes in chronic hepatitis C virus (HCV) infection (CHC). We aimed to clarify HCV replication is inhibited by Vit D in HCV replicon cells. Clinical implication was assessed for rapid virological response (RVR) and sustained virological response (SVR) among those patients receiving anti-viral therapy. METHODS: Cell survival and viral loads were observed in Con1 (genotype-1b) and J6/JFH (genotype-2a) cells treated with different doses of Vit D...
February 22, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28225572/daclatasvir-and-asunaprevir-for-genotype-1b-chronic-hepatitis-c-patients-with-chronic-kidney-disease
#2
Chisa Kondo, Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Toru Asano, Kai Yoshizawa, Tomomi Okubo, Yoshimichi Chuganji, Yoshio Aizawa, Etsuko Iio, Yasuhito Tanaka, Katsuhiko Iwakiri
AIM: To evaluate the efficacy and safety of daclatasvir and asunaprevir combined therapy in genotype 1b chronic hepatitis C (CHC) patients with non-dialysis chronic kidney disease (CKD). METHODS: In a multicenter collaborative study, 249 patients received 60 mg of daclatasvir (NS5A inhibitor) once a day and 100 mg of asunaprevir (NS3/4A protease inhibitor) twice a day for 24 weeks between September 2014 and September 2015 and were subjected to this analysis...
February 22, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28225289/-treatment-of-hcv-genotype-2%C3%A2-infection
#3
Petr Husa, Petr Husa
INTRODUCTION: Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. AIMS: Retrospectively evaluate the results of therapy of patients with genotype 2 HCV treated during last 15 years at the Department of Infectious Diseases University Hospital Brno and Faculty of Medicine Masaryk University Brno, Czech Republic. PATIENTS AND METHODS: 15 patients (9 men, 6 women, mean age 54.73 ± 13.83 years, median 54 years) with chronic genotype 2 infection were treated at in our department during last 15 years...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/28224470/three-patients-treated-with-sofosbuvir-plus-ledipasvir-for-recurrent-hepatitis-c-after-liver-transplantation
#4
Tomokazu Kawaoka, Michio Imamura, Kei Morio, Yuki Nakamura, Masataka Tsuge, Clair Nelson Hayes, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Kouhei Ishiyama, Hideki Ohdan, Kazuaki Chayama
We previously reported results of interferon (IFN)-free daclatasvir and asunaprevir for the treatment of recurrent hepatitis C virus (HCV) genotype 1 infection after liver transplantation (LT). Here we report three patients who achieved viral response with no effect on the blood concentrations of immunosuppressive agents following sofosbuvir plus ledipasvir treatment. The first patient was a 68-year-old female with HCV-related liver cirrhosis who failed to respond to pegylated-IFN and ribavirin (PEG-IFN/RBV) after living donor LT...
February 21, 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28224352/hcv-management-in-resource-constrained-countries
#5
REVIEW
Seng Gee Lim
With the arrival of all-oral directly acting antiviral (DAA) therapy with high cure rates, the promise of hepatitis C virus (HCV) eradication is within closer reach. The availability of generic DAAs has improved access to countries with constrained resources. However, therapy is only one component of the HCV care continuum, which is the framework for HCV management from identifying patients to cure. The large number of undiagnosed HCV cases is the biggest concern, and strategies to address this are needed, as risk factor screening is suboptimal, detecting <20% of known cases...
February 21, 2017: Hepatology International
https://www.readbyqxmd.com/read/28223719/hepatitis-c-virus-associated-pruritus-etiopathogenesis-and-therapeutic-strategies
#6
EDITORIAL
Youssef Alhmada, Denis Selimovic, Fadi Murad, Sarah-Lilly Hassan, Youssef Haikel, Mossaad Megahed, Matthias Hannig, Mohamed Hassan
In addition to its contributing role in the development of chronic liver diseases, chronic hepatitis C virus (HCV) infection is associated with extrahepatic manifestations, particularly, cutaneous-based disorders including those with pruritus as a symptom. Pruritus is frequently associated with the development of chronic liver diseases such as cholestasis and chronic viral infection, and the accumulation of bile acids in patients' sera and tissues as a consequence of liver damage is considered the main cause of pruritus...
February 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28223549/membranous-nephropathy-associated-with-hepatitis-c-virus-infection-treated-with-corticosteroids-and-ledipasvir-sofosbuvir-a-case-report-and-review-of-literature
#7
Qinjie Weng, Xiao Li, Hong Ren, Jingyuan Xie, Xiaoxia Pan, Jing Xu, Nan Chen
BACKGROUND: Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults. As many clinical cases have reported, it may be associated with hepatitis C virus (HCV) infection. Antiviral therapy can be various. CASE SUMMARY: We report a case of patient with chronic HCV infection and MN, who presented with was proteinuria. He was treated with ledipasvir and sofosbuvir (Harvoni; Gilead Sciences, Foster City, CA) and was found to be virus-free. CONCLUSION: We have reported this case to provide insight into whether Ledipasvir-Sofosbuvir should be administered for HCV-related glomerulonephritis...
February 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28222623/interferon-%C3%AE-induced-cd100-on-na%C3%A3-ve-cd8-t-cells-enhances-antiviral-responses-to-hepatitis-c-infection-through-cd72-signal-transduction
#8
Bing Jie Li, Yu He, Ying Zhang, Yong Hong Guo, Yun Zhou, Pei Xin Zhang, Wei Wang, Jie Ru Zhao, Jin Ge Li, Wei Ze Zuo, Chao Fan, Zhan Sheng Jia
Objectives We investigated the effects of CD100 on naïve CD8(+) T cells during hepatitis C virus (HCV) infection after interferon-α (IFN-α) therapy to clarify the mechanism underlying the effect of IFN-α in enhancing the antiviral response. Methods The CD100 molecules on subsets of CD8(+) T cells were analysed with flow cytometry. The effects of CD100-overexpressing naïve CD8(+) T cells were determined with ELISAs and an MTT cytotoxicity assay. The role of CD100-CD72 signal transduction was analysed with a neutralization and transwell assays...
February 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28222098/multicenter-study-of-skin-rashes-and-hepatotoxicity-in-antiretroviral-na%C3%A3-ve-hiv-positive-patients-receiving-non-nucleoside-reverse-transcriptase-inhibitor-plus-nucleoside-reverse-transcriptase-inhibitors-in-taiwan
#9
Pei-Ying Wu, Chien-Yu Cheng, Chun-Eng Liu, Yi-Chien Lee, Chia-Jui Yang, Mao-Song Tsai, Shu-Hsing Cheng, Shih-Ping Lin, De-Yu Lin, Ning-Chi Wang, Yi-Chieh Lee, Hsin-Yun Sun, Hung-Jen Tang, Chien-Ching Hung
OBJECTIVES: Two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) plus 1 non-NRTI (nNRTI) remain the preferred or alternative combination antiretroviral therapy (cART) for antiretroviral-naive HIV-positive patients in Taiwan. The three most commonly used nNRTIs are nevirapine (NVP), efavirenz (EFV) and rilpivirine (RPV). This study aimed to determine the incidences of hepatotoxicity and skin rashes within 4 weeks of initiation of cART containing 1 nNRTI plus 2 NRTIs. METHODS: Between June, 2012 and November, 2015, all antiretroviral-naive HIV-positive adult patients initiating nNRTI-containing cART at 8 designated hospitals for HIV care were included in this retrospective observational study...
2017: PloS One
https://www.readbyqxmd.com/read/28220833/early-hepatitis-b-surface-antigen-decline-predicts-treatment-response-to-entecavir-in-patients-with-chronic-hepatitis-b
#10
Cheng-Yuan Peng, Hsueh-Chou Lai, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen, Ching-Hsiang Chen
Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving entecavir treatment remain unclear. We prospectively enrolled 529 patients (195 hepatitis B e antigen [HBeAg]-positive and 334 HBeAg-negative) with a median treatment duration of 49.2 months. Median HBsAg levels declined significantly in both groups at Month 3, but only at Months 6-12 in the HBeAg-negative group. Both groups exhibited a significant HBsAg decline with each successive year of treatment...
February 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28220713/the-influence-of-targeted-temperature-management-on-the-pharmacokinetics-of-drugs-administered-during-and-after-cardiac-arrest-a-systematic-review
#11
Tessa Crombez, Said Hachimi-Idrissi
OBJECTIVE: Pharmacokinetic parameters of drugs are widely investigated under normothermic conditions and normal hemodynamic parameters. The European Resuscitation Council recommends the use of targeted temperature management (TTM) with a target temperature of 34 °C in cardiac arrest (CA) patients. The aim of this literature review is to investigate the influence of CA combined with TTM on the pharmacokinetics of drugs. Results of preclinical and clinical studies are compared with each other...
February 21, 2017: Acta Clinica Belgica
https://www.readbyqxmd.com/read/28220512/sofosbuvir-velpatasvir-voxilaprevir-with-or-without-ribavirin-in-daa-experienced-patients-with-genotype-1-hcv
#12
Eric Lawitz, Fred Poordad, Jennifer Wells, Robert H Hyland, Yin Yang, Hadas Dvory-Sobol, Luisa M Stamm, Diana M Brainard, John G McHutchison, Carmen Landaverde, Julio Gutierrez
: The optimal retreatment strategy for hepatitis C virus (HCV) genotype 1-infected patients who fail direct-acting antiviral (DAA)-based regimens remains unknown. In this phase 2, open-label study conducted at a single center in the United States, patients with HCV genotype 1 infection who previously failed to achieve sustained virologic response on a DAA-based regimen were randomized to receive treatment with a fixed-dose combination tablet of sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin for 12 weeks...
February 21, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28220039/hormone-signaling-and-fatty-liver-in-females-analysis-of-estrogen-receptor-%C3%AE-mutant-mice
#13
S Hart-Unger, Y Arao, K J Hamilton, S L Lierz, D E Malarkey, S C Hewitt, M Freemark, K S Korach
BACKGROUND: Treatment with estrogen in early menopausal women protects against development of hepatic steatosis and NAFLD but estrogen has undesirable side effects which negate its beneficial effects in pre- and post-menopausal women. Targeted therapies require better understanding of the target sites and mechanisms by which estrogen signaling exerts its protective effects in women. ERα is thought to be the primary mediator for estrogen signaling to protect against hepatic steatosis...
February 21, 2017: International Journal of Obesity: Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/28219889/rapid-and-rigorous-il-17a-production-by-a-distinct-subpopulation-of-effector-memory-t-lymphocytes-constitutes-a-novel-mechanism-of-toxic-shock-syndrome-immunopathology
#14
Peter A Szabo, Ankur Goswami, Delfina M Mazzuca, Kyoungok Kim, David B O'Gorman, David A Hess, Ian D Welch, Howard A Young, Bhagirath Singh, John K McCormick, S M Mansour Haeryfar
Toxic shock syndrome (TSS) is caused by staphylococcal and streptococcal superantigens (SAgs) that provoke a swift hyperinflammatory response typified by a cytokine storm. The precipitous decline in the host's clinical status and the lack of targeted therapies for TSS emphasize the need to identify key players of the storm's initial wave. Using a humanized mouse model of TSS and human cells, we herein demonstrate that SAgs elicit in vitro and in vivo IL-17A responses within hours. SAg-triggered human IL-17A production was characterized by remarkably high mRNA stability for this cytokine...
February 20, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28219772/evidence-based-recommendations-on-the-management-of-extrahepatic-manifestations-of-chronic-hepatitis-c-virus-infection
#15
REVIEW
Manuel Ramos-Casals, Anna Linda Zignego, Clodoveo Ferri, Pilar Brito-Zerón, Soledad Retamozo, Milvia Casato, Peter Lamprecht, Alessandra Mangia, David Saadoun, Athanasios G Tzioufas, Zobair M Younossi, Patrice Cacoub
∗The current therapeutic armamentarium against HCV has been recently expanded with an explosion of new molecules (DAAs) with high virological efficacy ∗The objective of this international consensus is to provide therapeutic recommendations for HCV patients with extrahepatic manifestations (EHM). ∗The use of non-antiviral therapeutic approaches should be evaluated according to the type of EHM and severity of the clinical presentation ∗B cell depletion with rituximab is the established biologic approach to cryoglobulinaemic vasculitis (CV) employed to date...
February 17, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28219610/bictegravir-versus-dolutegravir-each-with-emtricitabine-and-tenofovir-alafenamide-for-initial-treatment-of-hiv-1-infection-a-randomised-double-blind-phase-2-trial
#16
Paul E Sax, Edwin DeJesus, Gordon Crofoot, Douglas Ward, Paul Benson, Robin Dretler, Anthony Mills, Cynthia Brinson, Julie Peloquin, Xuelian Wei, Kirsten White, Andrew Cheng, Hal Martin, Erin Quirk
BACKGROUND: All recent treatment guidelines recommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy. Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a 10 day monotherapy study and has a high in-vitro resistance barrier. On the basis of these results, we did a phase 2 trial comparing bictegravir with dolutegravir. METHODS: In this randomised, double-blind, phase 2 trial, we recruited previously untreated adults (aged ≥18 years) with HIV-1 infections from 22 outpatient centres in the USA...
February 14, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28218867/-screening-diagnosis-treatment-and-follow-up-of-hepatitis-c-virus-related-liver-disease-national-consensus-guideline-in-hungary-from-15-october-2016
#17
Béla Hunyady, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, Gabriella Lengyel, Alajos Pár, Zoltán Péter, László Rókusz, Ferenc Schneider, Ferenc Szalay, István Tornai, Klára Werling, Mihály Makara
Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver...
February 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28218636/lobular-distribution-and-variability-in-hepatic-atp-binding-cassette-protein-b1-abcb1-p-gp-ontogenetic-differences-and-potential-for-toxicity
#18
Ngu Njei Abanda, Zoe Riches, Abby C Collier
The ATP Binding Cassette B1 (ABCB1) transporter has critical roles in endo- and xenobiotic efficacy and toxicity. To understand population variability in hepatic transport we determined ABCB1 mRNA and protein levels in total liver lysates sampled from 8 pre-defined sites (n = 24, 18-69 years), and in S9 from randomly acquired samples (n = 87, 7 days-87 years). ABCB1 levels did not differ significantly throughout individual livers and showed 4.4-fold protein variation between subjects. Neither mRNA nor protein levels varied with sex, ethnicity, obesity or triglycerides in lysates or S9 (that showed the same relationships), but protein levels were lower in pediatric S9 (p < 0...
February 17, 2017: Pharmaceutics
https://www.readbyqxmd.com/read/28217259/phase-3-trial-of-first-generation-protease-inhibitor-therapy-for-hepatitis-c-virus-human-immunodeficiency-virus-coinfection
#19
Kenneth E Sherman, Minhee Kang, Richard Sterling, Triin Umbleja, Kristen Marks, Jennifer J Kiser, Beverly Alston-Smith, Wayne Greaves, Adeel A Butt, The Actg Birth Study Team
AIM: To evaluate efficacy/safety of hepatitis C virus (HCV) protease inhibitor boceprevir with pegylated interferon (PEG-IFN) alfa and weight-based ribavirin (RBV) in a phase 3 trial. METHODS: A prospective, multicenter, phase 3, open-label, single-arm study of PEG-IFN alfa, weight-based RBV, and boceprevir, with a PEG-IFN/RBV lead-in phase was performed. The HCV/human immunodeficiency virus coinfected study population included treatment naïve (TN) and treatment experienced (TE) patients...
February 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28217256/interferon-free-regimens-in-patients-with-hepatitis-c-infection-and-renal-dysfunction-or-kidney-transplantation
#20
REVIEW
Evangelos Cholongitas, Chrysoula Pipili, George V Papatheodoridis
Treatment of patients with chronic kidney disease (CKD) and chronic hepatitis C (CHC) differs from that used in the general CHC population mostly when glomerular filtration rate (GFR) is below 30 mL/min, as sofosbuvir, the backbone of several current regimens, is officially contraindicated. Given that ribavirin free regimens are preferable in CKD, elbasvir/grazoprevir is offered in CHC patients with genotype 1 or 4 and ombitasvir/paritaprevir and dasabuvir in genotype 1b for 12 wk. Although regimens containing peginterferon with or without ribavirin are officially recommended for patients with CKD and genotype 2, 3, 5, 6, such regimens are rarely used because of their low efficacy and the poor safety and tolerance profile...
February 8, 2017: World Journal of Hepatology
keyword
keyword
12911
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"